HOME > REGULATORY
REGULATORY
- MHLW Panel to Discuss Opdivo for Hodgkin’s Lymphoma on Oct. 27
October 17, 2016
- Huge Costs, Amount of Application Data Required Will Be Major Challenges in Development of Biosimilars: Open Forum
October 14, 2016
- Health Minister to “Positively Consider” Setting Biosimilars Use Target
October 14, 2016
- AMED to Open Office in Washington D.C.
October 13, 2016
- 30% of Rejected Requests for Health Damage Compensation Due to Improper Drug Use: MHLW
October 12, 2016
- MHLW Study Group to Revise 75 Manuals on Serious ADRs in 19 Fields Over 5-Year Period
October 12, 2016
- MHLW to Consider Additional Penalties for Kaketsuken after Reviewing Its Report: Minister Shiozaki
October 11, 2016
- Current Information Disclosure for DPO Discussions Appropriate: Shiozaki
October 7, 2016
- Univ. of Tokyo and Kyoto Univ. Selected to Participate in Project to Train Biostatisticians: AMED
October 7, 2016
- Make “High-Level Investment” Credits Permanent under R&D Tax Break: Industry
October 6, 2016
- Chuikyo Green-Lights Basic Plans on “Optimal Use Guidelines,” Notification Letters
October 6, 2016
- Chuikyo OKs Application of Huge-Seller Re-Pricing to Opdivo; Payers Loath to Use Ono Sales Outlook for Calculation
October 6, 2016
- 2nd Round of Sakigake Invitations Gets Underway
October 5, 2016
- MOF Pushes for Overhaul of Drug Pricing System, Says It Can’t Address Pricy Meds
October 5, 2016
- Kaketsuken Faces Another Penalty over Encephalitis Vaccine Manufacturing
October 5, 2016
- MHLW, PMDA Set Up “Preparatory Offices” to Plan Future Support System for Startups
October 5, 2016
- MHLW Orders Nagoya Univ. to Probe Corrections Made to Diovan Paper
October 4, 2016
- Bayer Launches Recall of Hemophilia Med Kogenate over Potency Loss
October 4, 2016
- Drug Discovery Support Network to Announce Withdrawn Research Themes; Companies Will Be Able to Use This as “Negative Data”
October 4, 2016
- MHLW Says It Will Compile “Optimal Use Guidelines” for Keytruda Too
October 3, 2016
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
